Newly launched medicines Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla offset the impact of competition from biosimilars for established medicines.
For the treatment of solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and ROS1-positive, advanced non-small cell lung cancer.
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.